David Paterson
@davidantibiotic
Followers
4K
Following
19K
Media
44
Statuses
2K
Infectious Diseases Physician. Founder of MERINO clinical trials network. Director of ADVANCE-ID. Interests - clinical trial design, new antimicrobial agents.
Joined February 2015
RT @ADVANCE__ID: ✨We’re excited to have Dr Bao Qiongling join the ADVANCE-ID team! Get to know her in this short introduction. #WelcomeOnb….
0
1
0
RT @edenhelmi: Don’t miss our 11th Antibiotic Masterclass!.🗓️ Mini Masterclass: 19 Sept 2025.🗓️ Main Masterclass: 20 Sept 2025. ✅ CPD point….
0
3
0
RT @AliSMV7: How do I manage Difficult-to-Treat Pseudomonas aeruginosa infections?: Key Questions for Today’s Clinicians. .
0
100
0
RT @AMRActionFund: Nearly 45,700 people in #Germany died related to antibiotic-resistant pathogens in 2019, according to a new study led by….
cna.al
Antibiotic-resistant infections remain a major health threat in Germany, contributing to tens of thousands of deaths each year, according to a study conducted by the Robert Koch Institute (RKI), the...
0
8
0
RT @padstamundo: Well done @_ChitraRavi_ ! Probe‐capture targeted next‐generation sequencing for pathogen and antimicrobial resistance dete….
0
2
0
RT @AliSMV7: Advancing the management of prosthetic joint infections: a review of randomized controlled trials and emerging evidence. http….
0
47
0
RT @gardp_amr: 📅 Save the Date: ACC2026. The Antimicrobial Chemotherapy Conference (ACC2026) is coming your way in February 2026!. This yea….
0
8
0
Welcome Iris! So great to have you sharing your extensive experience with resistant GNBs with us!.
🚀 Join us in welcoming Dr Iris Chang to the ADVANCE-ID team! Here’s a brief introduction to get to know her better!. #WelcomeOnboard #ADVANCE_ID #AMR #ClinicalTrials #Research #Singapore
0
4
14
RT @ESCMID: Join us in Athens for the Ecraid/ESCMID course on 'Better methods for clinical studies in ID & CM' covering how to phrase a res….
0
4
0
RT @ESCMID: ⏰In 2 weeks: ESCMID/ISAC joint webinar on how hospital design directly impacts infection control. Speakers: Margreet Vos & Paul….
0
5
0
RT @ADVANCE__ID: 🚀 Join us in welcoming Dr Luca Mezzadri to the ADVANCE-ID team! Here’s a brief introduction to get to know him better!. #W….
0
1
0
RT @gardp_amr: 🩹💊 When lives are on the line, clinicians often reach for antibiotic combinations based on in vitro promise. But do they hel….
0
2
0
RT @ADVANCE__ID: We are pleased to announce that earlier this month, we enrolled the first patient into the CRGNB silo of the TREAT-GNB pla….
0
6
0
RT @ADVANCE__ID: 🚀 Join us in welcoming Dr Abi Manesh to the ADVANCE-ID team! Here’s a brief introduction to get to know him better!. #Welc….
0
3
0
RT @ADVANCE__ID: A new episode in the RESISTALKs podcast series is out! Dive into the BEATLE trial on extended vs bolus β-lactam infusions….
0
1
0
RT @TheLancet: Tetanus is a devastating neurological infection that remains a major cause of global morbidity and mortality. A new Review….
0
93
0
RT @ARLGnetwork: 🗓️On Thursday, July 10, @ARLGnetwork member @davidantibiotic will share his expertise in a webinar on designing adaptive c….
0
2
0
Amazing that 2 large trials using the PRACTical design have recruited their first patients within days of each other. NeoSep in children and TREAT-GNB in adults. Well done @gardp_amr and @ADVANCE__ID.
With the first baby enrolled in NeoSep1 Part 2, GARDP’s clinical trial on neonatal sepsis, GARDP's Sally Ellis shares why this matters -
0
8
27
RT @gardp_amr: With the first baby enrolled in NeoSep1 Part 2, GARDP’s clinical trial on neonatal sepsis, GARDP's Sally Ellis shares why th….
0
2
0
So excited that @ADVANCE__ID has commenced recruitment into our world first platform trial for carbapenem-resistant Gram negatives! @padstamundo @jesusrbano.
0
5
47